CSC
CVKD icon

Caldwell Sutter Capital’s Cadrenal Therapeutics CVKD Stock Holding History

Caldwell Sutter Capital’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17 Hold
5
– – ﹤0.01% 918
2026
Q1 		$26 Hold
5
– – ﹤0.01% 877
2025
Q4 		$34 Hold
5
– – ﹤0.01% 862
2025
Q3 		$69 Hold
5
– – ﹤0.01% 854
2025
Q2 		$60 Hold
5
– – ﹤0.01% 838
2025
Q1 		$88 Buy
+5
New +$92 ﹤0.01% 871

Other funds holding CVKD

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GBT
Grove Bank & Trust Miami, Florida $1.01B AUM 26.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

Caldwell Sutter Capital's CVKD Position: Q2 2026 in Review

Caldwell Sutter Capital held its Cadrenal Therapeutics (CVKD) position steady in Q2 2026 at 5 shares worth $17. The position accounts for ﹤0.01% of the portfolio, ranked #918.

Caldwell Sutter Capital first reported a position in CVKD in Q1 2025 and has held it in 6 quarters since. The position peaked at $88 in Q1 2025. 20 funds tracked by Wall St. Rank hold CVKD as of Q2 2026.

  • Caldwell Sutter Capital held 5 shares of Cadrenal Therapeutics worth $17 as of Q2 2026.
  • Caldwell Sutter Capital left its Cadrenal Therapeutics share count unchanged in Q2 2026.
  • Cadrenal Therapeutics made up ﹤0.01% of Caldwell Sutter Capital's portfolio in Q2 2026, its #918 holding.
  • Caldwell Sutter Capital first reported a position in Cadrenal Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Caldwell Sutter Capital's Cadrenal Therapeutics position peaked at $88 in Q1 2025.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q2 2026.

Based on Caldwell Sutter Capital's 13F filing for Q2 2026, filed 5 Aug 2026.